Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced that it has signed a merger agreement with Shanghai Fosun New Medical Research Co., Ltd. (Fosun New Medical) on June 24, 2024. According to the agreement, Fosun New Medical will absorb and merge with Henlius and proposes a privatization plan. After the merger is completed, Henlius will be deregistered in China and the listed status on the Stock Exchange of Hong Kong Limited (SEHK) will be canceled. The merger agreement includes a cancellation price of HKD 24.60 per H share and CNY 22.444794 per non-listed share. In addition, Fosun Pharma reserves the right to allow new investors to subscribe to or acquire shares of Fosun New Medical before the completion of the merger. The...Show More

Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) announced that it has signed a merger agreement with Shanghai Fosun New Medical Research Co., Ltd. (Fosun New Medical) on June 24, 2024. According to the agreement, Fosun New Medical will absorb and merge with Henlius and proposes a privatization plan. After the merger is completed, Henlius will be deregistered in China and the listed status on the Stock Exchange of Hong Kong Limited (SEHK) will be canceled. The merger agreement includes a cancellation price of HKD 24.60 per H share and CNY 22.444794 per non-listed share. In addition, Fosun Pharma reserves the right to allow new investors to subscribe to or acquire shares of Fosun New Medical before the completion of the merger. The merger is expected to be paid by internal cash resources and/or external debt financing, including loan financing from Fosun New Medical and the Shanghai Branch of China Merchants Bank Co., Ltd. The implementation conditions of the merger include obtaining approval from relevant government departments, approval from shareholders' meetings, and completion of other legal procedures. H shares were suspended from trading on May 23, 2024, and resumed trading on June 25, 2024. The effectiveness of the merger agreement is uncertain, and shareholders and potential investors should proceed with caution.